Risk factors for acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: Retrospective analysis of 73 patients who received cyclosporin A

Bone Marrow Transplantation

Volumn 40, Issue 9, 2007, Pages 875-880

  Izumi, N ^a   Furukawa, T ^b   Sato, N ^c   Okazuka, K ^a   Tsukada, N ^a   Abe, T ^a   Yano, T ^a   Kurasaki, T ^a   Masuko, M ^b   Toba, K ^a   Takahashi, M ^d   Aizawa, Y ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^c NAGAOKA RED CROSS HOSPITAL   (Japan)

^d NIIGATA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; METHOTREXATE;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INFUSION; DRUG MONITORING; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; PRIORITY JOURNAL; RADIOIMMUNOASSAY; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; RISK FACTOR; SHORT COURSE THERAPY;

ACUTE DISEASE; ADOLESCENT; ADULT; CYCLOSPORINE; DRUG MONITORING; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PREMEDICATION; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 35648958154     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705834     Document Type: Article

References (16)

1. Devergie A. Graft vs. host disease. In: Apperley J, Carreras E, Gluckman E, Gratwohl A, Masszi T (eds). Haemopoietic Stem Cell Transplantation European School of Hematology: Paris, 2004, pp 163-176.
2. Yee GC, Self SG, McGuire TR, Carlin J, Sanders JE, Deeg HJ. Serum cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic marrow transplantation. N Engl J Med 1988; 319 65-70.
3. Nash RA, Pepe MS, Storb R, Longton G, Pettinger M, Anasetti C et al. Acute graft-versus-host disease: Analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992; 80: 1838-1845.
4. Martin P, Bleyzac N, Souillet G, Galambrun C, Bertrand Y, Maire PH et al. Relationship between CsA trough blood concentration and severity of acute graft-versus-host disease after paediatric stem cell transplantation from matched-sibling or unrelated donors. Bone Marrow Transplant 2003; 32: 777-784.
5. Martin P, Bleyzac N, Souillet G, Galambrun C, Bertrand Y, Maire PH et al. Clinical and pharmacological risk factors for acute graft-versus-host disease after paediatric bone marrow transplantation from matched-sibling or unrelated donors. Bone Marrow Transplant 2003; 32: 881-887.
6. Ogawa N, Kanda Y, Matsubara M, Asano Y, Nakagawa M, Sakata-Yanagimoto M et al. Increased incidence of acute graft-versus-host disease with the continuous infusion of cyclosporine A compared to twice-daily infusion. Bone Marrow Transplant 2004; 33: 549-552.
7. Sato N, Furukawa T, Kuroha T, Hashimoto S, Masuko M, Takahashi H et al. High-dose cytosine arabinoside and etoposide with total body irradiation as a preparatory regimen for allogeneic hematopoietic stem-cell transplantation in patients with acute lymphoblastic leukemia. Bone Marrow Transplant 2004; 34: 299-303.
8. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
9. Schran HF, Rosano TG, Hassell AE, Pell MA. Determination of cyclosporine concentrations with monoclonal antibodies. Clin Chem 1987; 33 2225-2229.
10. Lindholm A, Napoli K, Rutzky L, Kahan BD. Specific monoclonal radioimmunoassay and fluorescence polarization immunoassay for trough concentration and area-under-the-curve monitoring of cyclosporine in renal transplantation. Ther Drug Monit 1992; 14: 292-300.
11. Halloran P. Calcineurin inhibition-relationship to cyclosporine blood concentration. Focus Med 1998; 13: 15-18.
12. Kahan BD. Therapeutic drug monitoring of cyclosporine: 20 years of progress. Transplant Proc 2004; 36: 378S-391S.
13. Nashan B, Cole E, Levy G, Thervet E. Clinical validation studies of Neoral C(2) monitoring: A review. Transplantation 2002; 73: S3-S11.
14. Levy G, Thervet E, Lake J, Uchida K, Consensus on Neoral C(2): Expert Review in Transplantation (CONCERT) Group. Patient management by Neoral C(2) monitoring: An international consensus statement. Transplantation 2002; 73: S12-S18.
15. Duncan N, Craddock C. Optimizing the use of cyclosporin in allogeneic stem cell transplantation. Bone Marrow Transplant 2006; 38: 169-174.
16. Ruutu T, Niederwieser D, Gratwohl A, Apperley JF. A survey of the prophylaxis and treatment of acute GVHD in Europe: A report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic leukaemia working party of the EBMT. Bone Marrow Transplant 1997; 19: 759-764.